Heard about Altimmune’s wild ride? The stock’s been on a heater, up over 70% this month, as retail investors bet big on a possible buyout. The company just raised $75 million to push its new liver drug into late-stage testing, and Wall Street’s starting to notice. The real buzz? With this cash, Altimmune can hold out for a better deal if Big Pharma comes knocking. If you’re into biotech drama, this is one to watch! #Business #LocalBusiness #Altimmune